[1]谢艳红.左氧氟沙星联合利福喷丁胶囊治疗老年初治肺结核患者的效果[J].医学信息,2021,34(17):151-153.[doi:10.3969/j.issn.1006-1959.2021.17.040]
　XIE Yan-hong.The Effect of Levofloxacin Combined with Rifapentine Capsule in the Treatment of Pulmonary Tuberculosis in the Elderly[J].Medical Information,2021,34(17):151-153.[doi:10.3969/j.issn.1006-1959.2021.17.040]
点击复制

左氧氟沙星联合利福喷丁胶囊治疗老年初治肺结核患者的效果()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年17期
页码:
151-153
栏目:
药物与临床
出版日期:
2021-09-01

文章信息/Info

Title:
The Effect of Levofloxacin Combined with Rifapentine Capsule in the Treatment of Pulmonary Tuberculosis in the Elderly
文章编号:
1006-1959（2021）17-0151-03
作者:
谢艳红
（黑山县全民健康保障中心结核病防治所门诊病房，辽宁 黑山 121400）
Author(s):
XIE Yan-hong
(The Outpatient Ward of the Tuberculosis Prevention and Treatment Institute of the National Health Security Center of Heishan County,Heishan 121400,Liaoning,China)
关键词:
左氧氟沙星; 利福喷丁胶囊; 肺结核; 肺部活性蛋白水平
Keywords:
Levofloxacin; Rifapentine capsule; Tuberculosis; Pulmonary active protein level
分类号:
R521
DOI:
10.3969/j.issn.1006-1959.2021.17.040
文献标志码:
A
摘要:
目的 研究左氧氟沙星联合利福喷丁胶囊治疗老年初治肺结核患者临床效果。方法 选取2017年1月-2019年12月我院治疗的54例老年初治肺结核患者为研究对象，采用随机数字表法分为对照组和观察组，各27例。对照组采用利福喷丁胶囊治疗，观察组在对照组基础上给予左氧氟沙星治疗，比较两组临床治疗总有效率、肺部活性蛋白水平[活性物质相关蛋白A（SP-A）和表面活性物质相关蛋白D（SP-D）]、不同时间点痰菌转阴率、炎症因子水平[白细胞介素-2（IL-2）、白细胞介素-10（IL-10）]、临床不良反应发生情况。结果 观察组治疗总有效率为92.59%，高于对照组的81.48%，差异有统计学意义（P＜0.05）；两组治疗后肺表面活性蛋白SP-A、SP-D表达均低于治疗前，且观察组低于对照组，差异有统计学意义（P＜0.05）；观察组治疗后2、4、6个月痰菌转阴率均高于对照组，差异有统计学意义（P＜0.05）；观察组IL-2、IL-10水平均低于对照组，差异有统计学意义（P＜0.05）；观察组不良反应发生率为7.41%，与对照组的11.11%比较，差异无统计学意义（P＞0.05）。结论 左氧氟沙星联合利福喷丁胶囊治疗老年初治肺结核效果确切，可有效改善肺部活性蛋白表达，促进痰菌转阴，且无严重不良反应。
Abstract:
Objective To study the clinical effects of levofloxacin and rifapentine capsule in the treatment of pulmonary tuberculosis patients in the early years.Methods A total of 54 elderly patients with newly diagnosed tuberculosis treated in our hospital from January 2017 to December 2019 were selected as the research objects. They were divided into a control group and an observation group by a random number table method, with 27 cases in each group.The control group was treated with rifapentine capsule, and the observation group was treated with levofloxacin on the basis of the control group.The total effective rate of clinical treatment, the level of active protein in the lung[surfactant-associated protein A(SP-A), surfactant-associated protein D(SP-D)], the negative rate of sputum bacteria at different time points, the level of inflammatory factors[interleukin-2 (IL-2), interleukin-10 (IL-10)], and the occurrence of clinical adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 92.59%, which was higher than 81.48% in the control group,the difference was statistically significant (P<0.05);After treatment, the expressions of lung surfactant protein SP-A and SP-D in the two groups were lower than before treatment, and the observation group was lower than the control group, the difference was statistically significant (P<0.05);The negative rate of sputum bacteria was higher than that of the control group at 2, 4, and 6 months after treatment,the difference was statistically significant (P<0.05);The levels of IL-2 and IL-10 in the observation group were lower than those in the control group,the difference was statistically significant(P＜0.05);The incidence of adverse reactions in the observation group was 7.41%, compared with 11.11% in the control group, the difference was not statistically significant(P>0.05).Conclusion The combination of levofloxacin and rifapentine capsule is effective in treating tuberculosis in the early ages. It can effectively improve the expression of active protein in the lungs and promote the conversion of sputum bacteria without serious adverse reactions.

参考文献/References:

[1]苏琼,刘洪兰,徐雅莉.预防性保肝治疗方案对初治肺结核患者的安全性和有效性分析[J].西部医学,2015,27(1):66-68. [2]施俊伟,张书岭.利福喷丁治疗肺结核临床疗效及安全性评价[J].中国地方病防治杂志,2015,8(5):407-408. [3]刘宇红,杜建,高微微,等.含链霉素或左氧氟沙星方案治疗复治肺结核患者的近期疗效及安全性[J].中国防痨杂志,2015,37(5):487-493. [4]刘君,周容仲.左氧氟沙星联合卷曲霉素治疗方案对耐多药肺结核患者免疫功能及肝功能的影响[J].海南医学院学报,2015,21(1):38－40. [5]董强,鲁平海,李少雄.利福喷丁与利福平治疗初治涂阳肺结核的疗效及对肝功能的影响[J].实用临床医药杂志,2015,19(19):125-127. [6]李利娟,何晶,李骁.利福喷汀联合左氧氟沙星治疗老年初治涂阳肺结核的疗效观察[J].海南医学,2016,27(16):2632-2634. [7]Tiberi S,D’Ambrosio L,De LS,et al.Ertapenem in the treatment of multidrug-resistant tuberculosis:first clinical experience[J].Eur Resp J,2016,47(1):333-336. [8]宋锁言,蒋海琴,王君,等.对2种中西医结合的化疗方案治疗老年初治肺结核的疗效及安全性比较[J].世界中医药,2017,12(3):570-572. [9]何涛.含左氧氟沙星、利福喷丁化疗方案对复治涂阳肺结核的临床疗效研究[J].国际呼吸杂志,2016,36(24):1855-1857. [10]郝峥,高秋莲.利福喷丁联合左氧氟沙星治疗初治菌阳肺结核近期疗效观察[J].临床肺科杂志,2015,18(10):1848-1849. [11]李鑫.肺结核合并气管支气管结核危险因素及诊断[J].医学信息,2020,33(1):32-35. [12]宁洪叶,蒋贤高,施伎蝉,等.左氧氟沙星及利福喷丁胶囊治疗老年初治肺结核患者的疗效及安全性分析[J].中国生化药物杂志,2017,37(4):238-240. [13]温俊霞,安贺娟,张进明,等.莫西沙星对耐多药肺结核患者血清降钙素原与C反应蛋白的影响[J].中国药业,2015,24 (21):45-47. [14]李宝龙.纤维支气管镜药物灌注联合莫西沙星对耐多药肺结核患者痰菌转阴率及血清T细胞亚群,PCT水平变化的影响[J].中国医学创新,2019,16(19):58-61. [15]肖兰春,陈利.左氧氟沙星治疗耐多药肺结核的临床疗效[J].中国医药科学,2017,7(6):37-39. [16]刘智,傅佳鹏,杨梁梓,等.左氧氟沙星和莫西沙星治疗耐多药肺结核临床疗效比较[J].临床肺科杂志,2017,22(4):711-714.

相似文献/References:

[1]李秀杰.含左氧氟沙星化疗方案治疗耐利福平结核病的预后分析[J].医学信息,2019,32(02):159.[doi:10.3969/j.issn.1006-1959.2019.02.048]
　LI Xiu-jie.Prognosis Analysis of Levofloxacin-containing Chemotherapy for Rifampicin-resistant Tuberculosis[J].Medical Information,2019,32(17):159.[doi:10.3969/j.issn.1006-1959.2019.02.048]
[2]冯瑞丰.阿奇霉素治疗急性细菌性下呼吸道感染的 有效性和安全性评价[J].医学信息,2019,32(11):152.[doi:10.3969/j.issn.1006-1959.2019.11.045]
　FENG Rui-feng.Evaluation of the Efficacy and Safety of Azithromycin in the Treatment of Acute Bacterial Lower Respiratory Tract Infections[J].Medical Information,2019,32(17):152.[doi:10.3969/j.issn.1006-1959.2019.11.045]
[3]隋文峰,潘 雪.左氧氟沙星联合头孢哌酮舒巴坦治疗老年肺炎的疗效及其对肺功能的影响[J].医学信息,2020,33(06):156.[doi:10.3969/j.issn.1006-1959.2020.06.052]
　SUI Wen-feng,PAN Xue.Effect of Levofloxacin Combined with Cefoperazone Sulbactam in the Treatment of Senile Pneumonia and Its Effect on Lung Function[J].Medical Information,2020,33(17):156.[doi:10.3969/j.issn.1006-1959.2020.06.052]
[4]陈 嫈.左氧氟沙星致上消化道出血再发2例报道[J].医学信息,2021,34(08):192.[doi:10.3969/j.issn.1006-1959.2021.08.054]
[5]魏长斌.头孢哌酮钠舒巴坦钠对糖尿病合并尿路感染的疗效及安全性分析[J].医学信息,2021,34(14):151.[doi:10.3969/j.issn.1006-1959.2021.14.042]
　WEI Chang-bin.Analysis of the Efficacy and Safety of Cefoperazone Sodium and Sulbactam Sodium on Diabetes Complicated with Urinary Tract Infection[J].Medical Information,2021,34(17):151.[doi:10.3969/j.issn.1006-1959.2021.14.042]
[6]谢艳红,冯 莉.左氧氟沙星对老年肺结核患者血清IL-6及IFN-γ水平的影响[J].医学信息,2021,34(16):118.[doi:10.3969/j.issn.1006-1959.2021.16.032]
　XIE Yan-hong,FENG Li.Effect of Levofloxacin on Serum IL-6 and IFN-γ Levels in Elderly Patients with Pulmonary Tuberculosis[J].Medical Information,2021,34(17):118.[doi:10.3969/j.issn.1006-1959.2021.16.032]
[7]张 翠,王 喆,杨悦杰,等.利福平联合多西环素及左氧氟沙星治疗布氏菌病的疗效[J].医学信息,2022,35(03):112.[doi:10.3969/j.issn.1006-1959.2022.03.027]
　ZHANG Cui,WANG Zhe,YANG Yue-jie,et al.Effect of Rifampicin Combined with Doxycycline and Levofloxacin in the Treatment of Brucellosis[J].Medical Information,2022,35(17):112.[doi:10.3969/j.issn.1006-1959.2022.03.027]
[8]曾小兰.阿莫西林-克拉维酸钾、左氧氟沙星治疗下呼吸道感染的疗效及成本-效果分析[J].医学信息,2022,35(18):77.[doi:10.3969/j.issn.1006-1959.2022.18.019]
　ZENG Xiao-lan.Efficacy and Cost-effectiveness Analysis of Amoxicillin-clavulanate Potassium and Levofloxacin in Treatment of Lower Respiratory Tract Infection[J].Medical Information,2022,35(17):77.[doi:10.3969/j.issn.1006-1959.2022.18.019]
[9]曾文宏,叶芳芳,周志明.哌拉西林钠他唑巴坦钠联合左氧氟沙星治疗慢性支气管炎的临床疗效及安全性观察[J].医学信息,2022,35(23):140.[doi:10.3969/j.issn.1006-1959.2022.23.029]
　ZENG Wen-hong,YE Fang-fang,ZHOU Zhi-ming.Observation on Clinical Efficacy and Safety of Piperacillin Sodium and Tazobactam Sodium Combined with Levofloxacin in the Treatment of Chronic Bronchitis[J].Medical Information,2022,35(17):140.[doi:10.3969/j.issn.1006-1959.2022.23.029]
[10]叶芳芳,周志明,曾文宏.哌拉西林钠他唑巴坦钠联合左氧氟沙星对支气管扩张患者气道功能、炎症反应的影响[J].医学信息,2023,36(01):103.[doi:10.3969/j.issn.1006-1959.2023.01.020]
　YE Fang-fang,ZHOU Zhi-ming,ZENG Wen-hong.Effect of Piperacillin Sodium and Tazobactam Sodium Combined with Levofloxacin on Airway Function and Inflammatory Response in Patients with Bronchiectasis[J].Medical Information,2023,36(17):103.[doi:10.3969/j.issn.1006-1959.2023.01.020]

更新日期/Last Update: 1900-01-01